Immunohistochemical profile and clinical-pathological variables in breast cancer

被引:3
作者
Duarte Cintra, Jane Rocha [1 ]
Bustamante Teixeira, Maria Teresa
Diniz, Roberta Wolp
Goncalves Junior, Homero
Florentino, Thiago Marinho
de Freitas, Guilherme Fialho
Mota Oliveira, Luiz Raphael
dos Reis Neves, Mariana Teodoro
Pereira, Talita
Guerra, Maximiliano Ribeiro
机构
[1] Hosp 9 Julho, Inst Oncol, BR-36010510 Juiz De Fora, MG, Brazil
来源
REVISTA DA ASSOCIACAO MEDICA BRASILEIRA | 2012年 / 58卷 / 02期
关键词
Progesterone receptors; erbB2; receptor; breast neoplasias; immunohistochemistry; estrogen receptors; Ki-67; antigen; ADJUVANT CHEMOTHERAPY; ESTROGEN-RECEPTOR; PROGESTERONE-RECEPTOR; SUBTYPES; TRASTUZUMAB; EXPRESSION; PROGNOSIS; PATTERNS; SURVIVAL; THERAPY;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Immunohistochemical profile and clinical-pathological variables in breast cancer Objective: To describe the main characteristics of women with breast cancer, according to the immunohistochemical profile. Methods: The population comprised a hospital cohort, consisting of women diagnosed with breast cancer between 2003 and 2005 (n = 601) and treated at a referral center for cancer care in Juiz de Fora, MG, Brazil. Only 397 women who had complete immunohistochemistry analysis were selected. To define the groups according to the immunohistochemical profile, the assessment of estrogen and progesterone receptors, Ki-67 cell proliferation index, and overexpression of human epidermal growth factor receptor 2 (HER2) was chosen. According to the different phenotypes, five subtypes were defined: luminal A, luminal B HER2 negative, luminal B HERZ positive, triple negative, and HER2 overexpression. Results: Most patients were white (80.7%) and post-menopausal (64.9%), with a mean age of 57.4 years (+/- 13.5). At diagnosis, 57.5% had tumor size >= 2.0 cm, and 41.7% had lymph node involvement. The most common subtypes were luminal B - HER2 negative (41.8%) and triple negative (24.2%). In the luminal A subtype, 72.1% of patients were post-menopausal, while the highest percentage of premenopausal women were observed in the luminal B - HER2 positive and triple negative subtypes (45.2% and 44.2%, respectively). A higher frequency of tumors > 2.0 cm and lymph node involvement was observed in triple negative and HER2 positive subtypes. Conclusion: This study allowed the distribution assessment of the main clinical and pathological characteristics and those related to health services in a cohort of Brazilian women with breast cancer, according to the immunohistochemical tumor subtypes.
引用
收藏
页码:178 / 187
页数:10
相关论文
共 50 条
[31]   Correlation between p53 expression and clinical-pathological characteristics of gastric cancer [J].
Radovanovic, Dragce ;
Knezevic, Milan ;
Canovic, Dragan ;
Acimovic, Ljubisa .
VOJNOSANITETSKI PREGLED, 2011, 68 (10) :832-836
[32]   Immunohistochemical determination of estrogen and progesterone receptors in breast cancer: relationship with clinicopathologic factors in 302 patients in Ivory Coast [J].
Effi, Ahoua Benjamin ;
Aman, Nguiessan Alphonse ;
Koui, Baumaney Sylvanus ;
Koffi, Kouadio Donatien ;
Traore, Zie Cheick ;
Kouyate, Mohamed .
BMC CANCER, 2017, 17
[33]   The Japanese breast cancer society clinical practice guidelines for pathological diagnosis of breast cancer, 2022 edition [J].
Honma, Naoko ;
Yoshida, Masayuki ;
Kinowaki, Keiichi ;
Horii, Rie ;
Katsurada, Yuka ;
Murata, Yuya ;
Shimizu, Ai ;
Tanabe, Yuko ;
Yamauchi, Chikako ;
Yamamoto, Yutaka ;
Iwata, Hiroji ;
Saji, Shigehira .
BREAST CANCER, 2024, 31 (01) :8-15
[34]   Clinical and pathological factors predictive of response to neoadjuvant chemotherapy in breast cancer: A single center experience [J].
Del Prete, Salvatore ;
Caraglia, Michele ;
Luce, Amalia ;
Montella, Liliana ;
Galizia, Gennaro ;
Sperlongano, Pasquale ;
Cennamo, Gregorio ;
Lieto, Eva ;
Capasso, Elena ;
Fiorentino, Olga ;
Aliberti, Maria ;
Auricchio, Annamaria ;
Iodice, Patrizia ;
Addeo, Raffaele .
ONCOLOGY LETTERS, 2019, 18 (04) :3873-3879
[35]   Molecular subtypes of breast cancer: prognostic implications and clinical and immunohistochemical characteristics [J].
Arrechea Irigoyen, M. A. ;
Vicente Garcia, F. ;
Cordoba Iturriagagoitia, A. ;
Ibanez Beroiz, B. ;
Santamaria Martinez, M. ;
Guillien Grima, F. .
ANALES DEL SISTEMA SANITARIO DE NAVARRA, 2011, 34 (02) :219-233
[36]   Immunohistochemical subtypes of the breast cancer in the ultrasound and clinical aspect - literature review [J].
Dobruch-Sobczak, Katarzyna ;
Gumowska, Magdalena ;
Maczewska, Joanna ;
Kolasinska-Cwikla, Agnieszka ;
Guzik, Pawel .
JOURNAL OF ULTRASONOGRAPHY, 2022, 22 (89) :93-99
[37]   CNS metastases of breast cancer show discordant immunohistochemical phenotype compared to primary [J].
Bachmann, C. ;
Grischke, E. M. ;
Fehm, T. ;
Staebler, A. ;
Schittenhelm, J. ;
Wallwiener, D. .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2013, 139 (04) :551-556
[38]   Primary lymphoma of the central nervous system - A clinical-pathological and immunohistochemical study of ten autopsy cases [J].
Costa, Henrique ;
Franco, Marcello ;
Hahn, Myriam Dumas .
ARQUIVOS DE NEURO-PSIQUIATRIA, 2006, 64 (04) :976-982
[39]   Immunohistochemical profile of breast cancer in young patients receiving care in a charity hospital in Brazil [J].
Chambo, Danielle ;
Nunes Moulin de Moraes, Janine ;
Coimbra Cremasco Tavares, Lais ;
Trigo Martinez, Yara ;
Chambo Filho, Antonio .
GAZZETTA MEDICA ITALIANA ARCHIVIO PER LE SCIENZE MEDICHE, 2018, 177 (1-2) :14-19
[40]   Progesterone receptor loss identifies luminal-type local advanced breast cancer with poor survival in patients who fail to achieve a pathological complete response to neoadjuvant chemotherapy [J].
Chen, Sheng ;
Huang, Liang ;
Chen, Can-Ming ;
Shao, Zhi-Ming .
ONCOTARGET, 2015, 6 (20) :18174-18182